--- title: "Quest Diagnostics Stock Smashes 52-Week High On Strong Quarter, Dividend Hike" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/275503019.md" description: "Quest Diagnostics (NYSE: DGX) reported Q4 earnings of $2.42 per share, exceeding expectations, with sales of $2.81 billion, up 7.1% YoY. The company announced a 7.5% increase in its quarterly cash dividend to 86 cents per share and a $1 billion increase in share repurchase authorization. For fiscal 2026, Quest expects adjusted earnings of $10.50-$10.70 per share and sales between $11.7-$11.82 billion. Shares rose 6.35% to $203.40, marking a new 52-week high." datetime: "2026-02-10T19:05:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275503019.md) - [en](https://longbridge.com/en/news/275503019.md) - [zh-HK](https://longbridge.com/zh-HK/news/275503019.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275503019.md) | [English](https://longbridge.com/en/news/275503019.md) # Quest Diagnostics Stock Smashes 52-Week High On Strong Quarter, Dividend Hike **Quest Diagnostics Incorporated** (NYSE:DGX) on Tuesday reported fourth-quarter adjusted earnings of $2.42 per share, beating the consensus of $2.36. The provider of diagnostic information services reported sales of $2.81 billion, up 7.1% year over year, beating the consensus of $2.75 billion. Consolidated organic revenues grew by 6.4%. “We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year,” said **Jim Davis**, Chairman, CEO, and President. “Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers’ needs and to form strategic collaborations supporting growth.” Operating income increased 7% to $386 million. Adjusted operating income was $429 million, or a margin of 15.3% compared to $409 million, or 15.6% of revenues, last year. Total volume, measured by the number of requisitions, increased 8.5% versus the fourth quarter of 2024, with organic volume up 7.9%. Total revenue per requisition was down 0.1% versus the prior year. CFO **Sam Samad** on Tuesday commented, “Corewell Health and Fresenius Medical Care deliver significant volume growth at a lower revenue per requisition than our company average. Excluding these two relationships, our organic volume growth accelerated to 4.1% in the fourth quarter, while our revenue per requisition growth remained solid at approximately 3.0%. Unit price remained consistent with our expectations.” ## Dividend Increase Quest Diagnostics also authorized a 7.5% increase in its quarterly cash dividend to 86 cents per share from 80 cents per share. As a result, the annual cash dividend will be $3.44 per share. ## Share Buyback Additionally, the Board of Directors has increased the company’s share repurchase authorization by $1 billion. The increased authority is in addition to the approximately $0.4 billion that was available as of December 31, 2025. ## Guidance “As we look ahead to 2026, our guidance reflects our continued confidence in our business strengths and market fundamentals, which include favorable demographic trends, increasing use of blood-based lab diagnostics, and growing interest in preventive health and wellness,” Davis said on Tuesday. Quest Diagnostics expects fiscal 2026 adjusted earnings of $10.50-$10.70 per share versus the consensus of $10.43. The company expects 2026 sales between $11.7-$11.82 billion compared to the consensus of $11.39 billion. **DGX Price Action:** Quest Diagnostics shares were up 6.35% at $203.40 at the time of publication on Tuesday. The stock is trading at a new 52-week high, according to Benzinga Pro data. _Photo via Shutterstock_ ### 相關股票 - [Quest Diagnostics (DGX.US)](https://longbridge.com/zh-HK/quote/DGX.US.md) ## 相關資訊與研究 - [Quest Diagnostics Earnings Preview: What to Expect](https://longbridge.com/zh-HK/news/280790410.md) - [Whoop has LeBron – now it wants your mom](https://longbridge.com/zh-HK/news/280860081.md) - [Energy Transfer stock is up big in 2026. Is there still time to get in?](https://longbridge.com/zh-HK/news/281629741.md) - [Individual investors could get a rare shot at buying into SpaceX from day one](https://longbridge.com/zh-HK/news/281225223.md) - [18:35 ETLU Investors Have Opportunity to Lead Lufax Holding Ltd Securities Fraud Lawsuit First Filed by the Firm](https://longbridge.com/zh-HK/news/280888597.md)